Literature DB >> 3746592

Retinoblastoma: correlation between age at diagnosis and survival.

D H Abramson, R M Ellsworth, N Grumbach, L Sturgis-Buckhout, B G Haik.   

Abstract

Life tables analyses were performed from the records of 1147 patients seen between 1958 and 1983 to determine correlation between age at diagnosis and survival from metastatic retinoblastoma. No difference was noted overall in survival from metastatic retinoblastoma for unilateral vs. bilateral, male vs female, or family history vs negative family history. Survival rate of 21 of 40 patients diagnosed after age 7 and receiving no treatment was 96%. Two patients in this group did develop metastasis: one because of late diagnosis and one because treatment was refused. One patient with an "arrested retinoblastoma" showed growth in his third decade, necessitating treatment. Survival was poorest in patients diagnosed between ages two and seven years where mortality was 19% from metastatic retinoblastoma. Patients diagnosed between birth and two years had an intermediate survival of 95%. Because of second nonocular tumors, survival of the patient with unilateral retinoblastoma was significantly better than that of the bilaterally affected child.

Entities:  

Mesh:

Year:  1986        PMID: 3746592     DOI: 10.3928/0191-3913-19860701-06

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  10 in total

Review 1.  The diagnosis of retinoblastoma.

Authors:  D H Abramson
Journal:  Bull N Y Acad Med       Date:  1988-05

2.  Retinoblastoma. Continuum of care.

Authors:  J N Simmons; M A Zabrycki
Journal:  Can Fam Physician       Date:  1993-06       Impact factor: 3.275

3.  Characteristics and clinical presentations of pediatric retinoblastoma in North-western Iran.

Authors:  Reza Nabie; Nazli Taheri; Ali Mahdavi Fard; Rohollah Fadaei Fouladi
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

4.  Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma.

Authors:  E Ferrari Marback; V E A Arias; A Paranhos; F A Soares; A L Murphree; C M Erwenne
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

5.  Unilateral retinoblastoma: new intraocular tumours after treatment.

Authors:  D H Abramson; L S Gamell; R M Ellsworth; E F Kruger; C A Servodidio; L Turner; D Sussman
Journal:  Br J Ophthalmol       Date:  1994-09       Impact factor: 4.638

6.  Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma.

Authors:  Dong Yoon Kim; Jeong A Choi; Jae-Young Koh; Young Hee Yoon
Journal:  J Exp Clin Cancer Res       Date:  2016-11-04

7.  Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma.

Authors:  Anderson H Webb; Bradley T Gao; Zachary K Goldsmith; Andrew S Irvine; Nabil Saleh; Ryan P Lee; Justin B Lendermon; Rajini Bheemreddy; Qiuhua Zhang; Rachel C Brennan; Dianna Johnson; Jena J Steinle; Matthew W Wilson; Vanessa M Morales-Tirado
Journal:  BMC Cancer       Date:  2017-06-20       Impact factor: 4.430

8.  Presenting signs of retinoblastoma at a tertiary level teaching hospital in Ethiopia.

Authors:  Jemal Zeberga Shifa; Alemayehu Mekonnen Gezmu
Journal:  Pan Afr Med J       Date:  2017-09-22

9.  Adhesion G protein-coupled receptor, ELTD1, is a potential therapeutic target for retinoblastoma migration and invasion.

Authors:  Jonathan Guihurt Santiago; Neikelyn Burgos-Tirado; Daniella Dorta Lafontaine; José C Mendoza Sierra; Roberto Herrera Camacho; Clara M Vecchini Rodríguez; Vanessa Morales-Tirado; Jacqueline Flores-Otero
Journal:  BMC Cancer       Date:  2021-01-11       Impact factor: 4.430

10.  Management of retinoblastoma in older children (>5 years) using intra-arterial chemotherapy: Comparison of outcomes to prechemotherapy and intravenous chemotherapy eras.

Authors:  Evan B Selzer; R Joel Welch; Pascal Jabbour; Ann M Leahey; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.